New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with cold agglutinin disease, a serious and chronic autoimmune hemolytic anemia
- Phase 3 data from the CADENZA study met the primary composite endpoint with statistical significance; secondary endpoint data were clinically meaningful
- Findings provide further evidence that sutimlimab results in rapid inhibition of C1-activated hemolysis within one week of treatment and had a sustained treatment effect throughout the study
PARIS – June 11, 2021 – Results from Part A of CADENZA, a pivotal Phase 3 double-blind, placebo-controlled study evaluating the safety and efficacy of sutimlimab in people with cold agglutinin disease (CAD) without a recent history of blood transfusion (within the prior six months), will be presented in an oral session at the European Hematology Association 2021 Congress. The data demonstrated treatment with sutimlimab resulted in rapid and sustained inhibition of C1-activated hemolysis in people with CAD, noted within one week of treatment, and clinically significant improvements in hemoglobin and fatigue when compared to placebo during the course of the study.
“Cold agglutinin disease causes the body’s immune system to mistakenly destroy its healthy red blood cells. People living with cold agglutinin disease experience the crippling impact of chronic hemolysis that can cause severe anemia, profound fatigue and can have acute hemolytic crisis,” said principal investigator and presenting author Professor Alexander Röth, M.D., Department of Hematology and Stem Cell Transplantation, University Hospital, University of Duisburg-Essen, Germany. “The positive evidence from the CADENZA trial demonstrate significant improvements in hemolysis and meaningful impact on key measures of anemia and fatigue.”
CADENZA is a second pivotal Phase 3 study investigating sutimlimab in the treatment of CAD. The primary efficacy outcome was the proportion of patients who met all three of the following components: improvement in hemoglobin ≥1.5 g/dL from baseline at treatment assessment timepoint, (average of Weeks 23, 25, and 26); avoidance of transfusions from Week 5 through Week 26; and avoidance of other CAD-related therapies beyond what was permitted from Week 5 through Week 26. The secondary efficacy measures assessed improvement from baseline in key indicators of the disease process including hemoglobin, bilirubin, lactate dehydrogenase (LDH) levels, and quality of life as measured by Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score.
“The results from CADENZA and data from the Phase 3 CARDINAL study, presented as a late-breaker at the American Society of Hematology congress in 2019, will be the basis of our filing with the European Medicines Agency. Together, the studies highlight the promising potential of sutimlimab to have a meaningful impact for people living with CAD,” said Karin Knobe, M.D., Ph.D., Head of Development, Rare and Rare Blood Disorders, Sanofi. “Based on the robust clinical evidence we have to-date, sutimlimab significantly inhibits hemolysis and has the potential to be an important new treatment for CAD.”
CADENZA Phase 3 study data (final Part A) presented at EHA 2021
The CADENZA trial is a Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of sutimlimab in patients with CAD without a recent history of blood transfusion (within the past 6 months). Eligible patients were randomized 1:1 to receive a fixed weight-based dose (6.5g or 7.5g) of sutimlimab or placebo via intravenous infusion on Day 0, Day 7 and then once every other week up to Week 26. The open-label Part B of the study is ongoing and will evaluate long-term safety as well as durability of response to sutimlimab in all participants with CAD.
Forty-two patients (mean age of 66.7 years) were enrolled and randomized to either sutimlimab (N=22) or placebo (N=20). Overall, 19 (86%) and 20 (100%) patients in the sutimlimab and placebo groups, respectively, completed Part A and continued into Part B. Three (14%) patients from the sutimlimab group discontinued Part A early due to adverse events.
Efficacy and safety data:
- Seventy-three percent (n=16) of patients treated with sutimlimab met the primary composite endpoint, demonstrating improvement in hemoglobin ≥1.5 g/dL from baseline at treatment assessment timepoint (Weeks 23, 25, and 26); avoidance of transfusions from Week 5 through Week 26; and avoidance of other CAD-related therapies beyond what was permitted from Week 5 through Week 26 compared to 15% (n=3) in the placebo group (Odds Ratio=15.9, 95% CI: 2.9 to 88.0, p<0.001).
- Data showed sutimlimab increased and sustained mean hemoglobin levels from baseline to treatment assessment timepoint (Week 26) representing a statistically significant least squares (LS) mean difference of 2.6 g/dL (p<0.001; 95% CI:1.8 to 3.4) when compared with placebo. Hemoglobin improved rapidly, with a LS mean increase from baseline of ≥1 g/dL by Week 1 and ≥2 g/dL by Week 3. Overall mean hemoglobin levels were maintained >11 g/dL from Week 3 through treatment assessment timepoint, demonstrating a sustained effect throughout the remainder of the treatment period.
- A statistically significant improvement in fatigue as measured by FACIT-Fatigue assessment was achieved in patients treated with sutimlimab when compared to the placebo group, 10.8 points versus 1.9, respectively, with a LS mean difference of 8.9 points (p<0.001; 95% CI:4.0 to 13.9). A 5 or greater point increase in FACIT-Fatigue score suggests a clinically important change. 1
- Patients treated with sutimlimab had greater mean reductions in bilirubin, a key marker of hemolysis, from baseline to treatment assessment timepoint as compared with the placebo group (-22.1 μmol/L versus -1.8 μmol/L, respectively). Mean bilirubin levels were normalized below the upper limit of normal within 1 to 3 weeks in the sutimlimab group (upper limit of reference range 20.5 µmol/L) and maintained levels below the upper limit of normal to week 26.
- Treatment with sutimlimab led to meaningful improvements in LDH, an additional hemolysis marker, from baseline to treatment assessment timepoint compared to placebo ( -150.8 U/L versus +7.6 U/L).
- Twenty-one patients (95.5%) in the sutimlimab group and 20 patients (100%) in the placebo group experienced at least one treatment emergent adverse event (TEAE).
- Three patients (13.6%) in the sutimlimab group experienced at least one treatment-emergent serious adverse event (TESAE) (n=4), including one TESAE assessed by the investigator as related to sutimlimab (cerebral venous thrombosis in a patient with a history of diabetes). One patient (5%) in the placebo group had three TESAEs.
- Treatment emergent adverse events reported more often in the sutimlimab group vs. placebo (difference of ≥ 3 patients between groups) were: headache (23% versus 10%), hypertension (23% versus 0%), rhinitis (18% versus 0%), Raynaud’s phenomenon (18% versus 0%), and acrocyanosis (14% versus 0%). No deaths or meningococcal infections were reported.
Cold agglutinin disease, a rare and chronic condition
Cold agglutinin disease (CAD) is a rare, chronic autoimmune hemolytic anemia that causes the body’s immune system to mistakenly attack healthy red blood cells and cause their destruction (hemolysis) via activation of the classical complement pathway. CAD patients may experience chronic anemia, profound fatigue, acute hemolytic crisis, and other potential complications, including an increased risk of thromboembolic events and early death.2,3,4 CAD impacts the lives of an estimated 12,000 people in the U.S., Europe, and Japan.5 Currently there are no approved therapies for CAD.
About CARDINAL Phase 3 Study
CARDINAL was the first of two pivotal Phase 3 studies investigating sutimlimab as a potential treatment for CAD. CARDINAL is an open-label, single-arm study to assess the efficacy and safety of sutimlimab in adult patients with CAD who received a recent blood transfusion. The CARDINAL data were presented in the Late-Breaking Abstracts Session at the 61st Annual Meeting of the American Society of Hematology in December 2019 and are the basis of the Biologics License Application submission with the U.S Food and Drug Administration (FDA).
Sutimlimab is an investigational, humanized monoclonal antibody that is designed to selectively target and inhibit C1s in the classical complement pathway, which is part of the innate immune system. By blocking C1s, sutimlimab inhibits the activation of the classical complement pathway with the goal of halting C1-activated hemolysis in CAD to prevent the abnormal destruction of healthy red blood cells. By selectively inhibiting the classical pathway upstream at C1s, sutimlimab does not inhibit the lectin and alternative complement pathways.
Sutimlimab has been granted Breakthrough Therapy by the U.S. Food and Drug Administration (FDA) and Orphan Drug status by the FDA, European Medicines Agency (EMA) and the Pharmaceuticals and Medical Devices Agency in Japan. Sutimlimab is currently under clinical investigation and has not been approved by any regulatory authority. Sanofi plans to resubmit its Biologics License Application with the U.S FDA in the second half of 2021.
- Hill Q, et al. Important Change in FACIT-Fatigue Score for Patients with Cold Agglutinin Disease: An Analysis Using the Phase 3 CARDINAL and CADENZA Studies. Poster presentation European Hematology Association Congress July 2021
- Broome C, et al. Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis. Res Pract Thromb Haemost. 2020;00:1–8.
- Quentin A. Hill, Rajeshwari Punekar, Jaime Morales Arias, Catherine M Broome, Jun Su; Mortality Among Patients with Cold Agglutinin Disease in the United States: An Electronic Health Record (EHR)-Based Analysis. Blood 2019; 134 (Supplement_1): 4790.
- Lauren C. Bylsma, Anne Gulbech Ording, Adam Rosenthal, Buket Öztürk, Jon P. Fryzek, Jaime Morales Arias, Alexander Röth, Sigbjørn Berentsen; Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease. Blood Adv 2019; 3 (20): 2980–2985.
- Berentsen S, et al. Haematologica. 2006;91(4):460-466
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Media Relations Contacts
Tel.: +1 (781) 264-1091
Investor Relations Contacts Paris
Investor Relations Contacts North America
IR main line:
Tel.: +33 (0)1 53 77 45 45
|Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2020. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.